Education
About Us
Working with TipRanks
Follow Us
RedHill Biopharma (RDHL)
NASDAQ:RDHL
RDHL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.71 - $20.28
Previous CloseN/A
Volume5.64K
Average Volume (3M)17.25K
Market Cap
$4.65M
Enterprise Value$1.29K
Total Cash (Recent Filing)$7.01M
Total Debt (Recent Filing)$2.28M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 14, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,295,345
10 Day Avg. Volume16,348
30 Day Avg. Volume17,251
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)-0.49
Price to Sales (P/S)0.00
P/FCF Ratio-0.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
RedHill Biopharma News
PremiumCompany Announcements
RedHill Biopharma Initiates Phase 2 Prostate Cancer Study
PremiumCompany Announcements
RedHill Biopharma Approves Key Resolutions at Annual Meeting
PremiumCompany Announcements
RedHill Biopharma Secures Warrant Exercise with Price ReductionPremiumCompany Announcements
RedHill Biopharma Secures Asset Freeze in Legal Victory Over Kukbo
PremiumCompany Announcements
RedHill Biopharma Postpones Annual Shareholders Meeting Due to Lack of QuorumOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and Individual Investors
RDHL FAQ
What was RedHill Biopharma’s price range in the past 12 months?
RedHill Biopharma lowest stock price was $1.71 and its highest was $20.27 in the past 12 months.
What is RedHill Biopharma’s market cap?
RedHill Biopharma’s market cap is $4.65M.
When is RedHill Biopharma’s upcoming earnings report date?
RedHill Biopharma’s upcoming earnings report date is Aug 14, 2025 which is in 37 days.
How were RedHill Biopharma’s earnings last quarter?
Currently, no data Available
Is RedHill Biopharma overvalued?
According to Wall Street analysts RedHill Biopharma’s price is currently Overvalued.
Does RedHill Biopharma pay dividends?
RedHill Biopharma does not currently pay dividends.
What is RedHill Biopharma’s EPS estimate?
RedHill Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RedHill Biopharma have?
RedHill Biopharma has 2,295,345 shares outstanding.
What happened to RedHill Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of RedHill Biopharma?
Currently, no hedge funds are holding shares in RDHL
Company Description
RedHill Biopharma
RedHill Biopharma (RDHL) is a specialty biopharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal and infectious diseases. The company is headquartered in Israel and operates primarily in the pharmaceutical sector, offering a range of products aimed at addressing significant medical needs in these areas.